ASCO® 2023


Presentation Times

Session Info Card

Seagen Development Pipeline

Seagen Development Pipeline

Enfortumab Vedotin | Urothelial Cancer | Abstract #4568

Enfortumab vedotin (EV) with or without pembrolizumab (P) in cisplatin-ineligible patients (pts) with previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Additional 3-month follow-up on cohort K data

Enfortumab Vedotin | Bladder Cancer | Abstract #4595

Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H

Enfortumab Vedotin | Bladder Cancer | Abstract #4596

A first-in-human trial of intravesical enfortumab vedotin (EV), an antibody-drug conjugate (ADC), in patients with non-muscle invasive bladder cancer (NMIBC): Interim results of a phase 1 study (EV-104)

Enfortumab Vedotin | Bladder Cancer | Abstract #TPS4601

KEYNOTE-905/EV-303: A phase 3 study to evaluate the efficacy and safety of perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC)

Enfortumab Vedotin | Head and Neck Cancer | Abstract #6017

Enfortumab vedotin in the previously treated advanced head and neck cancer (HNC) cohort of EV-202

Tucatinib | Biliary Tract Cancer | Abstract #4007

Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019): A phase 2 basket study

Tucatinib | Breast Cancer | Abstract #1051

Real-world patient characteristics and treatment patterns associated with tucatinib therapy in patients with HER2+ metastatic breast cancer

Tucatinib | Breast Cancer | Abstract #TPS1115

HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (trial in progress)

Tucatinib | Colorectal Cancer | Abstract #3528

HER2 testing in the MOUNTAINEER trial: Analysis of treatment response based on central HER2 assessment using IHC/ISH and NGS

Tucatinib | Colorectal Cancer | Abstract #TPS3631

MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first line treatment in HER2+ metastatic colorectal cancer (trial in progress)

SGN-B6A | Solid Tumors | Abstract #3024

SGN-B6A, an integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors: Updated results from a phase 1 study (SGNB6A-001)

SGN-BB228 | Solid Tumors | Abstract #TPS9597

Phase 1 study of SGN-BB228, an investigational CD228 x 4-1BB costimulatory antibody anticalin bispecific, in patients with advanced melanoma and other solid tumors (SGNBB228-001: trial in progress)